Table 1 (abstract P303). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Variable | CYC N=12 | MMF N=8 | TOT N=20 | P value |
|---|---|---|---|---|
Age at Tstart (years)–m±DS | 14,50±1,98 | 14,00±2,56 | 14,30±2,18 | 0,969 |
Untreated disease duration (days)–m±DS | 456,08±661,50 | 145,88±146,08 | 153,00±534,33 | 0,374 |
SLEDAI-2K at T0–m± DS | 18,08±7,59 | 18,87±7,99 | 18,40±7,55 | 0,846 |
WBC < 4000/mm3 – n (%) | 7 (58,3) | 4 (50,0) | 11 (55,0) | >0,999 |
Hb < 11 g/l – n (%) | 9 (75,0) | 4 (50,0) | 13 (65,0) | 0,356 |
PTL < 150000/mm3 – n (%) | 4 (33,3) | 2 (25,0) | 6 (30,0) | >0,999 |
ESR > 28 mm/h – n (%) | 5 (41,7) | 5 (62,5) | 10 (50,0) | 0,650 |
C3 <0 ,90 g/L – n (%) | 11 (91,7) | 7 (87,5) | 18 (90,0) | 0,999 |
Proteinuria > 0,5 g/die – n (%) | 7 (58,3) | 4 (50,0) | 11 (55,0) | 0,999 |